Sugi Predict

Sugi Predict / Compounds / SCHEMBL3546340

SCHEMBL3546340

SCHEMBL3546340

COC(=O)C1C=CCN1C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 2/20 0.39
▸ NR1H2 P55055 1/20 0.37
▸ NR1H3 Q13133 1/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ PREP P48147 1/20 0.36
▸ PDE4B Q07343 1/20 0.36
▸ ACE P12821 1/20 0.36
▸ CTSK P43235 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35
▸ RELA Q04206 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ CHRM2 P08172 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ CHRM3 P20309 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2559556 1.00 PTPN1 (0.39) PTPN1NR1H2NR1H3NPC1PREP
SCHEMBL3546343 1.00 PTPN1 (0.39) PTPN1NR1H2NR1H3NPC1PREP
SCHEMBL31375026 0.90 PREP (0.38) NR1H2NPC1PREPACECTSK
SCHEMBL10137609 0.90 PREP (0.38) NR1H2NPC1PREPACECTSK
SCHEMBL28773549 0.85 NR1H2 (0.38) PTPN1NR1H2NR1H3NPC1PDE4B
SCHEMBL25175295 0.84 ACE (0.47) NR1H2NPC1PREPACECTSK
SCHEMBL629586 0.84 ACE (0.47) NR1H2NPC1PREPACECTSK
SCHEMBL629585 0.84 ACE (0.47) NR1H2NPC1PREPACECTSK
SCHEMBL13519523 0.84 NFKB1 (0.41) PREPACECTSKLMNANPSR1
SCHEMBL6789639 0.84 NFKB1 (0.41) PREPACECTSKLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117049999-A Preparation method of Nemactetvir intermediate 重庆博腾制药科技股份有限公司 2023-11-14 — — CN claimed
US-20260022118-A1 HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS UNIV TEXAS (US) 2026-01-22 — — US disclosed
WO-2025108443-A2 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE SWITZERLAND GMBH (CH) 2025-05-30 — — WO disclosed
WO-2024215862-A2 HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-10-17 — — WO disclosed
CN-114436929-B Synthesis method of N-protected 3, 4-dehydro-L-proline ester 都创(重庆)医药科技有限公司 2024-08-13 — — CN disclosed
CN-117049999-A Preparation method of Nemactetvir intermediate 重庆博腾制药科技股份有限公司 2023-11-14 — — CN disclosed
CN-117049999-A Preparation method of Nemactetvir intermediate 重庆博腾制药科技股份有限公司 2023-11-14 — — CN disclosed
CN-116731044-A Pyrimidine-containing polycyclic biological inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-09-12 — — CN disclosed
US-20230083012-A1 DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2023-03-16 — — US disclosed
WO-2022161448-A1 DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES Janssen Sciences Ireland Unlimited Company (IE) 2022-08-04 — — WO disclosed
US-9499519-B2 Fused pyrimidine compounds and use thereof MEDIVATION TECHNOLOGIES, INC. (US) 2016-11-22 — — US disclosed
US-20160068513-A1 FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF MEDIVATION TECHNOLOGIES, INC. (US) 2016-03-10 — — US disclosed
WO-2014105958-A2 FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF MEDIVATION TECHNOLOGIES, INC. (US) 2014-07-03 — — WO disclosed
US-8071766-B2 HSP90 inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-06 — — US disclosed
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 — — US disclosed
US-20090042854-A1 Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-02-12 — — US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 — — US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 — — EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 — — EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068513-A1 FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF IGF1R, FGFR3, FGFR1 PTPN1 1231/4885NR1H2 1691/4885NR1H3 1919/4885
US-20090042854-A1 Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists TACR1, PROKR1, TACR2 PTPN1 2307/4885NR1H2 3926/4885NR1H3 4251/4885
US-20260022118-A1 HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS NRAS, KRAS, HRAS PTPN1 53/4885NR1H2 404/4885NR1H3 347/4885
US-20230083012-A1 DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES DPYD, HAVCR2, TYMP PTPN1 1863/4885NR1H2 142/4885NR1H3 150/4885
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE PTPN1 2663/4885NR1H2 3381/4885NR1H3 3101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.